Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Joel Ledford

Physician Assistant Tallahassee, FL Physician Assistant

NPI 1164425732 CMS profile 11097947

3334 Capital Medical Blvd, Suite 400, Tallahassee, FL 32308

Open in the dashboard

General payments

$6,523

319 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joel Ledford of Tallahassee, FL is reported in the CMS Open Payments database as having received $6,523 across 319 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,494 57
2024 General $1,374 69
2023 General $1,040 53
2022 General $1,309 72
2021 General $1,306 68

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joel Ledford
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Joel Ledford were reported at $1,494. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Joel Ledford Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,306 $132 $37–$438 $132
2022 $1,309 $155 $48–$522 $149
2023 $1,040 $167 $52–$557 $160
2024 $1,374 $178 $55–$600 $164
2025 $1,494 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Regeneron Healthcare Solutions, Inc. $1,436 56 payments
  2. AstraZeneca Pharmaceuticals LP $1,277 53 payments
  3. GlaxoSmithKline, LLC. $933 79 payments
  4. Genzyme Corporation $614 26 payments
  5. Novartis Pharmaceuticals Corporation $407 20 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $385 19 payments
  7. Amgen Inc. $252 12 payments
  8. Genentech USA, Inc. $247 9 payments
  9. Grifols USA, LLC $202 10 payments
  10. Incyte Corporation $139 3 payments
  11. Other $630 32 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,391 317 payments
  2. Education $132 2 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $1,175 51 payments
  2. DUPIXENT Inflammation And Immunology $952 41 payments
  3. TRELEGY ELLIPTA $652 47 payments
  4. FASENRA $554 19 payments
  5. DUPIXENT Immunology And Inflammation $484 15 payments
  6. SPIRIVA RESPIMAT $442 23 payments
  7. BREZTRI $422 14 payments
  8. NUCALA $395 39 payments
  9. AIRSUPRA $349 13 payments
  10. AREXVY $260 19 payments
  11. Other $2,531 118 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

732

Median for Physician Assistant: 241

Drug cost

$128,953

Median for Physician Assistant: $4,110

Branded share of claims

35.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 14 $50,534
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 22 $15,233
Breyna Budesonide/Formoterol Fumarate Brand 49 $12,615
Symbicort Budesonide/Formoterol Fumarate Brand 42 $11,341
Ipratropium Bromide Generic 192 $9,901
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 33 $6,067
Azelastine Hcl Generic 115 $4,839
Breo Ellipta Fluticasone/Vilanterol Brand 11 $4,104
Wixela Inhub Fluticasone Propion/Salmeterol Brand 23 $2,900
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 13 $2,894

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $274
  • GENZYME CORPORATION $205
$479 14 —
XOLAIR
  • Genentech USA, Inc. $135
  • Novartis Pharmaceuticals Corporation $84
$219 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $122
$122 — —
TEZSPIRE
  • Amgen Inc. $66
  • AstraZeneca Pharmaceuticals LP $35
$101 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $71
$71 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

319 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record